COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.